Disease or Syndrome
With subpar sales for Leqembi, Eisai delays Alzheimers patient goal deadline
Leqembi, Alzheimer’s Disease, Eisai, subpar sales
UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records
J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders
Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal
Lilly reports mid-stage win for tirzepatide in fatty liver disease
tirzepatide, Nonalcoholic Steatohepatitis, liver scarring, Lilly reports, MASH, Clinical Trials
4DMT’s Gene Therapy Reduces Eylea Injections, Advancing Plans for Phase 3 Trial in Wet AMD
Glycogen storage disease type II, 4DMT, gene therapy, Trial Phase
Novo Nordisk Gets 2023 Profit Beat Fueled by Ozempic, Wegovy Sales Spike
Nordisk, Ozempic, Constant – dosing instruction fragment, exchange rate
Sanofi gains AATD hopeful with $1.7-billion deal for Inhibrx
sanofi, Inhibrx, Acquisition (action), alpha 1-Antitrypsin Deficiency, Market
Lonza closes plant in China but CDMO’s sales signal an uptick in industry
Plants, China, Signal, Industry, Congestive heart failure
Fake versions of Novo Nordisk’s Ozempic linked to 3 dangerous hypoglycemia cases in US: Reuters
Hypoglycemia, Case (situation), Ultrasonography, Nordisk’s, United States Food and Drug Administration
Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis
Eosinophilic esophagitis, Dupixent, Child, Treatment intent, sanofi, Regeneron